欢迎来到天天文库
浏览记录
ID:55097959
大小:345.19 KB
页数:4页
时间:2020-05-09
《玻璃体腔内注射Bevacizumab治疗年龄相关性黄斑变性.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、国际眼科杂志2010年3月第10卷第3期www.IJO.cn电话:029—8224517283085628电子信箱:IJO.2000@163.corn·临床研究·玻璃体腔内注射Bevacizumab治疗年龄相关性黄斑-,-tr~又性刘文杰,高磊,东长霞,于华军,姜凯,林旭明作者单位(264000)中国山东省烟台市,青岛大学医学院附属烟0.98;P=0.004)showedsignificantimprove—mentsover台毓璜顶医院眼科baselinevalues.BCVAwasimprovedbyatIeasttwoIines作者简介:刘文杰,男,在读硕士
2、研究生,研究方向:眼底病。in18eyes(60%),remainedstablein8eyes(27%)atthe通讯作者:高磊,男,硕士生导师,主任医师,研究方向:眼底病.Iastvisit.AtotaIof58injectionswereperformedandtheGL6365@yahoo.eon1.enaveragenumberofinjectionswas1.93inthegroup.收稿日期:2009—12—19修回日期:2010—02—24About50%ofre—injectionsgainedatJeasttwolinesofvisionimp
3、rovementoneweekfollowingthere—treatment.NoseriousOCUlarorsystemicadverseeventswereIntravitrealinjectionofBevacizumabinobserved.treatment0fAMD·CONCLUS10N:IntravitreaIinjectionofbevacizumabforexudativeAMDwaswelItoleratedwithanimprovementWen·JieLiu,LeiGao,Chang-XiaDong,Hua—JuninBCVA.CFTa
4、ndTMVoverthemean9.7monthsfoIlow—Yu,KaiJiang,Xii—MingLinupperiod.Re.injectionofjntravitreaJbevacizumabshouldbeadministeredifneeded.DepartmentofOphthalmology,YantaiYuhuangdingHospital·KEY\^/0RDS:maculardegenerati0n/drugtherapy;ch0rOidaIAffiliatedtoMedicalCollegeofQingdaoUniversity",Yant
5、ai264000,neOvascuIarizatiOn/drugtherapy;antibodies,monoclonal/ShandongProvince,Chinatherapeuticuse:bevacizumabCOrrespOndenceto:LeiGao.DepartmentofOphthalmology,YantaiYuhuangdingHospitalAffiliatedtoMedicalCollegeofLiuWJ,GaoL,DongCX,eta1.IntravitrealinjectionofQingdaoUniversity,Yantai26
6、4000,ShandongProvince,China.BevacizumabintreatmentofAMDImJOphthalmol(CuojiYankeGL6365@yahoo.con.enzazhi)2010;10t3:540·543Received:2009—12-19Accepted:2010—02—24摘要Abstract目的:评估抗血管内皮生长因子单克隆抗体bevaeizumab·AlM:T0evaluatethesafetyandefficacyofintravitreaI(Avastin)玻璃体腔注射治疗湿性年龄相关性黄斑变性bevacizum
7、abfAvastininjectioninpatientswithexudative(age—relatedmaculardegeneration,AMD)的疗效和安全性。age—relatedmaculardegenerationfAMD).方法:对30例接受玻璃体腔注射bevacizumab(2.5mg)治·METHODS:Therecordsofpatientstreatedwith疗的AMD患者进行回顾分析,主要评价指标包括最佳矫intravitreaIiniectionof2.5mgbevacizumabforAMDwere正视力(best.correc
8、tedvi
此文档下载收益归作者所有